Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 18, 2018
Event: Entry into a Material Definitive Agreement (Item 1.01).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a contractual amendment.
Material Changes
On December 18, 2018, the Company entered into Amendment No. 6 to its License Agreement with the University of Virginia Patent Foundation (d/b/a the University of Virginia Licensing and Ventures Group). The primary change is the extension of the deadline required for the initiation of the Phase 3 clinical trial to December 31, 2019.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the amendment to extend the clinical trial timeline.
Risks and Contingencies: The filing does not explicitly detail new risks, though the extension of the Phase 3 trial initiation date implies a delay in the development timeline compared to previous schedules.
Investor Verification Checklist
- Verify the specific terms of Amendment No. 6 (Exhibit 10.1) regarding any financial obligations or milestone adjustments associated with the extension.
- Confirm the impact of the new December 31, 2019, Phase 3 initiation deadline on the Company's projected cash burn and capital requirements.
- Review prior filings to understand the original deadline and the reasons necessitating this extension.